Most Clicked StoriesMore >


UnitedHealth drops Lantus, Neupogen from formulary

PCMA SmartBrief | Sep 22, 2016

UnitedHealth Group beginning next year will no longer cover Sanofi's Lantus insulin and will move Eli Lilly and Co.'s biosimilar Basaglar insulin to Tier 1 and Novo Nordisk's Levemir to Tier 2. UnitedHealth will also cover Novartis' biosimilar Zarxio rather than Amgen's Neupogen. Reuters (09/22)


PBMs negotiated big discounts on expensive HCV drugs

PCMA SmartBrief | Sep 22, 2016

PCMA suggests ways to reduce opioid abuse, lower drug prices

PCMA SmartBrief | Sep 26, 2016

PCMA testifies before House subcommittee, offers policy options to curb Rx abuse, reduce costs

PCMA SmartBrief | Sep 23, 2016

Novum follows in footsteps of Valeant, Turing, Mylan

PCMA SmartBrief | Sep 27, 2016

PCMA: MAC lists help payers keep drug prices under control

PCMA SmartBrief | Sep 26, 2016

Release of draft guidance for biosimilar interchangeability moved by FDA

PCMA SmartBrief | Sep 23, 2016

Abbott reps pulled out all the stops to promote OxyContin

PCMA SmartBrief | Sep 22, 2016

Mylan CEO grilled in hearing over EpiPen price hikes

PCMA SmartBrief | Sep 22, 2016

Senators ask HHS IG for probe of Medicaid rebate program

PCMA SmartBrief | Sep 21, 2016


Find PCMA SmartBrief Issues by Date:





Sign up for PCMA SmartBrief



Designed specifically for PBM industry professionals, PCMA SmartBrief is a FREE, daily e-mail newsletter. It provides the the most relevant and actionable PBM industry news in a quick, easy to read format. Learn more